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AbstrAct
Glioblastoma multiforme (GBM) is a deadly grade IV brain tumor. Radiation 
in combination with temozolomide (TMZ), the current chemotherapeutic for GBMs, 
only provides 12–14 months survival post diagnosis. Because GBMs are dependent 
on both activation of the DNA damage pathway and the endoplasmic reticulum (ER) 
stress response, we asked if a novel ER stress inducing agent, JLK1486, increases 
the efficacy of TMZ.
We found that the combination of TMZ+JLK1486 resulted in decreased 
proliferation in a panel of adherent GBM cells lines and reduced secondary sphere 
formation in non- adherent and primary lines. Decreased proliferation correlated with 
increased cell death due to apoptosis. We found prolonged ER stress in TMZ+JLK1486 
treated cells that resulted in sustained activation of the unfolded protein response 
(UPR) through increased levels of BiP, ATF4, and CHOP. In addition, TMZ+JLK1486 
treatment caused decreased RAD51 levels, impairing DNA damage repair. Furthermore, 
we found delayed time to tumor doubling in TMZ+JLK1486 treated mice.
Our data shows that the addition of JLK1486 to TMZ increases the efficaciousness 
of the treatment by decreasing proliferation and inducing cell death. We propose 
increased cell death is due to two factors. One, prolonged ER stress driving the 
expression of the pro-apoptotic transcription factor CHOP, and, second, unresolved 
DNA double strand breaks, due to decreased RAD51 levels. The combination of 
TMZ+JLK1486 is a potential novel therapeutic combination and suggests an inverse 
relationship between unresolved ER stress and the DNA damage response pathway.
IntroductIon
Glioblastoma multiforme (GBM) is an aggressive 
grade IV brain tumor associated with low patient survival 
[1]. The current standard of care, comprised of surgical 
resection, radiation, and the chemotherapeutic agent 
temozolomide (TMZ), provides the majority of patients with 
a mere 12 to 14 month survival period post diagnosis [2, 3]. 
The rapid disease progression and low survival of 
GBM patients is due to a combination of factors. GBM 
tumors are highly aggressive and infiltrate into normal 
brain tissue, making complete surgical resection nearly 
impossible. Additionally, multidrug resistant pumps in 
the blood brain barrier (BBB) block chemotherapeutics’ 
access to the brain, limiting the number of effective 
drugs available to GBM patients [4]. Furthermore, these 
heterogeneous tumors are in a hypoxic environment 
[5–7]. This reduces the efficaciousness of radiation 
and leads to highly resistant cells harboring a variety 
of protective mutations, allowing them to survive and 
re-populate the tumor bed. All these factors contribute to 
inevitable tumor recurrence. There is an urgent need to 
improve the current standard of care for GBM patients. 
In order to do so, we asked if the novel combination 
of an endoplasmic reticulum stress inducer and TMZ 
enhances efficacy.
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TMZ is an oral alkylating DNA agent that efficiently 
crosses the BBB [8–10]. The majority of DNA alkyl 
groups, 70% at N7 guanine and 9.2% at N3 adenine, 
are ultimately not catastrophic as they are repaired by 
either base excision (BER) or nucleotide excision repair 
(NER)[10]. However, a small percent of adducts occur 
on the O6 site of guanine (5%)[10]. Because neither 
BER nor NER recognizes and excises this alkylated base, 
these adducts are deleterious to the cell [10]. During 
replication, the adduct triggers futile mismatch repair, 
resulting in stalled replication forks and single stranded 
breaks, which are converted into double stranded breaks 
(DSBs) during a second round of replication [11, 12]. 
These DSBs, if not repaired, result in G2/M arrest and 
eventual cell death [13, 14]. GBM tumors, in particular 
recurrent ones, circumvent the formation of TMZ-induced 
DSBs by increasing expression of methyl guanine methyl 
transferase (MGMT), an enzyme that removes the alkyl 
group from the O6 guanine site [15]. MGMT restores 
base integrity, thereby allowing the cell to successfully 
complete its’ cell cycle. Furthermore, detection of the 
O6 methyl adduct is dependent on a mismatch repair 
(MMR) response. Cells with mutated MMR proteins do 
not detect the O6 methyl adduct, allowing propagation of 
cells with highly damaged genomes. Because GBM cells 
are dependent on the DNA damage response pathway, 
treating cells with two agents, one that induces DNA 
damage (TMZ) and one that inhibits DNA damage repair, 
may increase tumor cell death [16–19]. To explore this 
hypothesis, we asked if an endoplasmic reticulum (ER) 
stress inducer interferes with DNA repair.
JLK1486 is a novel ER stress-inducing agent 
[20– 28]. Although this drug is not electrophilic enough to 
react with DNA, it can react with thiol residues, interfering 
with the formation of disulfide bonds essential for tertiary 
folding of proteins [20]. The resulting accumulation of 
unfolded and misfolded proteins triggers ER stress and 
activates the unfolded protein response (UPR) [29, 30]. 
Initially the UPR is protective; the three receptors that 
govern UPR, Ire1, ATF6, and PERK, initiate a signaling 
cascade that increases molecular chaperones, such as BiP/
GRP78, while stalling the translation of mRNAs, giving 
the ER time to resolve this stress [29, 31]. However, 
prolonged UPR switches from pro-survival to pro-death 
through upregulation of transcription factors, ATF4 and 
CHOP, which initiate apoptosis [32–36]. ATF4 is integral 
to this process as it not only increases CHOP expression 
during prolonged ER stress, but also promotes autophagy 
[37]. This initial cytoprotective mechanism becomes 
cytotoxic if the cell is unable to restore ER homeostasis, 
emphasizing the vital role of ER-mediated cell survival 
or cell death. It has been suggested that either blocking 
ER associated degradation (ERAD) of misfolded proteins 
or by inducing more ER stress, one may force a switch 
from pro-survival to pro-apoptosis [31, 38]. Blocking of 
ERAD in some cancers, such as multiple myeloma, is 
utilized in the clinic with some success; the FDA approved 
bortezomib in 2003 for this purpose [39, 40]. However, 
the use of drugs that inhibit ERAD are limited due to 
off target toxic effects [41]. Exacerbating ER stress is an 
attractive alternative. GBMs are solid tumors with cells 
that survive hypoxia, nutrient deprivation, and low pH. 
GBM cells have increased BiP/GRP78 levels, suggesting 
an intrinsic dependence on the ER stress pathway for 
survival [42]. Interference with the ER stress pathway may 
be detrimental to cell survival [43, 44].
We tested if the addition of JLK1486 to TMZ 
increased the efficaciousness of therapy. We reasoned that 
formation of DNA DSBs occurring in the presence of an 
overwhelming ER stress response would be catastrophic 
to cell survival. We found that JLK1486 induces ER stress 
in GBM cells and when combined with TMZ, reduces 
proliferation. Decreased proliferation correlated with 
increased apoptosis. Interestingly, in combination treated 
cells, we observed decreased RAD51 expression, a key 
protein for repair of DNA DSBs. We propose reduction 
of RAD51 levels as the mechanism that accounts for 
prolonged and unresolved DNA DSBs and increased 
apoptosis. Combination of JLK1486 with TMZ may 
provide a potential new chemotherapeutic regimen and, 
more intriguingly, may link unresolved ER stress with 
interference of DNA damage repair.
results
JlK1486 is active as a single agent
To determine the efficacy of JLK1486 as a single 
agent, we utilized a panel of GBM adherent, non-
adherent, and primary lines. For the majority of our 
established adherent GBM lines, a low concentration of 
JLK1486 inhibited proliferation (Figure 1A–1E; U87MG 
IC50 = 0.6 µM; A172 IC50 = 0.26 µM; U118MG IC50 
= 0.87 µM; LN18 IC50 = 0.27 µM); however, one line, 
T98G, was relatively resistant to JLK1486 (Figure 1D; 
T98G IC50 = 7.6 µM). To assess the efficacy of JLK1486 
in both converted non-adherent and primary lines, we 
employed neurosphere assays in which spheres are 
dissociated, single cells are plated at clonal density, 
drug treated, and allowed to grow. On either the seventh 
(converted non-adherent cell lines) or tenth day (primary 
cell lines), neurospheres, defined as a single sphere 
containing ten or more cells, were counted to measure 
the effects increasing concentrations of JLK1486 had on 
growth. We found our two converted non-adherent cell 
lines, U87NS and U118NS, were sensitive to JLK1486 
(Figure 1F–1G; U87NS IC50 = 1.6 µM; U118NS IC50 = 
0.13 µM). Our primary lines, GS8-26 and 5075, were also 
sensitive to JLK1486, with an IC50 of 0.08 µM in both 
lines (Figure 1H–1I).
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JlK1486 combined with tMZ reduces 
secondary sphere formation more effectively 
than JlK1486 or tMZ as single agents
Secondary sphere formation assays are an in vitro 
tool to mimic the clinical recurrence universally exhibited 
in GBM patients. Cell lines are dissociated, plated at 
clonal densities, drug treated and allowed to grow for 
seven or ten days. Fresh medium is added on day seven 
(U87NS, U118NS) or ten (GS8-26, 5075), and cells are 
allowed to grow an additional seven (U87NS, U118NS) 
or ten (GS8-26, 5075) days, and then counted, allowing 
cell and sphere recovery to be assessed. On day fourteen 
(U87NS, U118NS) or day twenty (GS8-26, 5075), spheres 
are dissociated to single cells, re-plated, allowed to grow 
for an additional seven (U87NS, U118NS) or ten days 
(GS8-26, 5075), and then counted to assess secondary 
sphere formation (Supplementary Figure 1A–1B). To 
determine if JLK1486 as a single agent was capable of 
blocking secondary sphere formation, we carried out a 
neurosphere formation assay with U87NS cells using a 
range of JLK1486 doses from 0 µM to 20 µM. Although 
JLK1486 alone at the IC50 for U87NS (2 µM) (Figure 2A) 
did not completely block secondary sphere formation, 
there was a statistically significant reduction of day 21 
secondary spheres compared to the DMSO control sample. 
A higher dose of JLK1486 (20 µM, ten times higher than 
the IC50) completely blocked secondary sphere formation 
(Figure 2A). Reduced sphere formation suggests that 
JLK1486 may be a novel chemotherapeutic for decreasing 
recurrence. 
This led us to ask if the efficacy of TMZ, the 
chemotherapeutic agent currently used in the clinic, 
could be improved if used in combination with JLK1486. 
We performed secondary sphere formation assays using 
TMZ alone (the relevant dose of TMZ in our converted 
non-adherent lines has been previously described [45]) 
and in combination with a sub-IC50 dose of JLK1486 
(1 µM) as well as the IC50 dose (2 µM) in U87NS cells 
(Supplementary Figure 1C). We did not find a statistically 
Figure 1: JlK1486 has activity as a single agent. (A–e) Determination of JLK1486 single agent IC50s in adherent lines via MTS 
assay. Relative absorbance at 490 nm is shown. (F–I) Determination of JLK1486 single agent IC50s in non-adherent and primary lines 
generated by day 7 neurosphere formation counts. N = 3, all error bars are SEM.
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significant reduction of secondary spheres for the sub-
optimal dose of TMZ+ 1 µM JLK1486 when compared to 
TMZ alone (Figure 2B). We did find significant reduction 
of secondary sphere formation in TMZ + 2 µM JLK1486 
versus TMZ or JLK1486 alone (Figure 2B). However, 
there was not a complete block in secondary sphere 
formation in the TMZ+2 µM JLK1486 dose, indicated by 
the statistically significant increase in sphere formation in 
day 14 versus day 21 samples (Figure 2B).
In the clinic GBM patients receive multiple doses 
of chemotherapeutics [2, 3]. We asked if two doses 
of JLK1486 would increase the efficaciousness of the 
TMZ+JLK1486 combination treatment. We carried out 
secondary sphere formation assays in which cells were 
dosed with TMZ+JLK1486 on day 0 and then treated a 
second time with JLK1486 alone on day 7 (Supplementary 
Figure 1D). We found significant secondary sphere 
reduction in the sub-optimal dose combination of TMZ+ 
1 µM JLK1486 2X versus TMZ+ 1 µM JLK1486 1X 
(Figure 2C versus Figure 2B) as well as inhibition of 
secondary sphere formation in TMZ+ 2 µM JLK1486 
2X versus TMZ+ 2 µM JLK1486 1X (Figure 2C 
versus Figure 2B). Additionally, we found significantly 
decreased secondary sphere formation in our converted 
non-adherent U118NS line as well as our primary lines 
GS8-26 and 5075 when cells were treated on day 0 
with TMZ+ JLK1486 and a second time with JLK1486 
on day 7 (Figure 2D– 2F). This demonstrates that the 
TMZ+ JLK1486 2X is an effective combination therapy 
to decrease secondary sphere formation and may be a 
schedule-dependent process. All further experiments were 
conducted using TMZ+JLK1486 2X .
tMZ+JlK1486 treatment results in decreased 
cell growth and increased cell death in u87ns
To determine how TMZ+2 µM JLK1486 treatment 
reduced secondary sphere formation in U87NS cells, we 
carried out a time course ranging from 24 hours to 23 
days to evaluate the number of trypan blue positive and 
negative cells. Control cells treated with DMSO had 
the highest rate of proliferation from day 0 to day 14 
Figure 2: JlK1486 alone does not block secondary sphere formation but when combined with tMZ, secondary 
sphere formation in decreased. (A) Secondary sphere formation assay of U87NS cells treated with JLK1486 alone, one time on 
day 0 (n = 3). (b) Secondary sphere formation assay of U87NS cells treated with TMZ+JLK1486. Cells were dosed one time on day 0 
with both agents (n = 4). (c) Secondary sphere formation assay of U87NS cells treated with TMZ+JLK1486. Cells were dosed on day 0 
with both TMZ+JLK1486 and a second time with JLK1486 on day 7 (n = 6). (d) Secondary sphere formation of U118NS cells treated 
with TMZ+JLK1486 on day 0 and a second time with JLK1486 on day 7 (n = 3). (e) Secondary sphere formation of primary line GS8-26 
cells treated with both TMZ+JLK1486 on day 0 and with JLK1486 on day 7 (n = 3). (F) Secondary sphere formation of primary line 5075 
cells treated with both TMZ+JLK1486 on day 0 and JLK1486 on day 7 (n = 3). NC = not counted because neurospheres were too numerous. 
All error bars are SEM, two-tailed t-test, *P = 0.01, **P = 0.001-0.007,***P = 0.0002-0.0005,****P < 0.0001.
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(Figure 3A). Cells treated with either 1 µM or 2 µM 
JLK1486 increased in number from day 0 to day 14, 
however, there were significantly fewer JLK1486-
treated cells versus the DMSO control (Figure 3A). 
Cells treated with either TMZ alone or TMZ in 
combination with 1 µM or 2 µM JLK1486 did not 
undergo significant proliferation from day 0 to day 
14 (Figure 3A). This was expected as it has been well 
established in the literature that TMZ induces DNA 
double strand breaks that result in G2/M arrest. After 
day 14 dissociation and re-plating, DMSO, 1 µM and 2 
µM JLK1486-treated cells, as well as TMZ alone treated 
cells underwent significant proliferation from day 16 
to day 23 (Figure 3A–3B). Although the number of 
TMZ+1 μM JLK1486- treated cells was less than TMZ 
alone treated cells on day 23, this was not statistically 
significant (Figure 3B). However, cells treated with 
TMZ+2 µM JLK1486 were incapable of repopulating 
their cultures and maintained a statistically significant 
reduction in cell number versus JLK1486 alone as well 
as TMZ alone (Figure 3B). This suggests that inhibition 
of secondary sphere formation in TMZ+2 µM JLK1486-
treated cells is at least partly the result of treated cells’ 
inability to proliferate.
We simultaneously collected trypan-blue-positive 
counts to detect cell death in U87NS control, single 
agent, and TMZ+JLK1486-treated cells. We observed 
significant increases in cell death in TMZ alone as well as 
TMZ+1 μM JLK1486 and TMZ+2 µM JLK1486-treated 
cells versus DMSO and 1 µM and 2 µM JLK1486 single-
treated cells in the first half of our time course (Figure 3C; 
days 0-14). However, post day 14, we observed a 
significant decrease in the percentage of trypan blue 
positive cells from day 16 to day 23 in TMZ alone treated 
cells (Figure 3C). Although the percentage of trypan-blue-
positive TMZ+1 µM JLK1486 cells also decreased for 
samples post day 14, the percent remained significantly 
higher than TMZ or 1 µM JLK1486 alone (Figure 3C). 
Conversely, the percent of trypan-blue-positive cells in 
TMZ+2 µM JLK1486-treated cells continued to increase 
post day 14 (Figure 3C). This resulted in a 70.0% (+/− 
5.0) trypan-blue-positive population in TMZ+ 2 µM 
JLK1486-treated cells versus 14.3% (+/− 3.2) in TMZ-
treated cells and 10.3% (+/− 3.9) in 2 µM JLK1486-
treated cells (Figure 3D). 
To test if the observed increase in cell death was 
due to apoptosis, we performed FACS analysis with 
annexin V and propidium iodide (PI) staining of 23-day 
samples. The annexinv V and PI staining corroborated our 
trypan blue counts as we observed 70.6% double positive 
cells in TMZ + 2 µM JLK1486-treated cells versus 3.9% 
in DMSO, 2.6% in 2 µM JLK1486 alone, and 2.3% in 
TMZ alone treated cells (Figure 3E–3H; 3I–3J). This 
demonstrates that TMZ + 2 µM JLK1486 treatment in 
U87NS cells results in reduced cell growth due to the 
induction of apoptosis.
tMZ+JlK1486 treatment induces prolonged 
endoplasmic reticulum stress that results 
in induction of cHoP, a pro-apoptotic 
transcription factor
It is well established that prolonged, unresolved ER 
stress triggers apoptosis [32–34]. To determine if TMZ + 
2 µM JLK1486 treatment results in prolonged ER stress 
induction, we collected a series of protein lysates over a 
24-hour to 23-day time course. We probed protein lysates 
for levels of BiP, a key heat shock molecular chaperone 
indicative of ER stress, as well as ATF4, a transcription 
factor that initially serves as a pro-survival signal but 
switches to pro-apoptotic when ER stress is unresolved. 
ATF4 drives increased expression of the pro-apoptotic 
transcription factor CHOP. We therefore analyzed protein 
lysates for ATF4 and CHOP to detect this switch.
In 2 µM JLK1486 and TMZ + 2 µM JLK1486-
treated cells we observed increased expression of BiP 
that was maintained 14 days post treatment, suggesting 
that JLK1486 induces prolonged ER stress (Figure 4). For 
post treatment day 14, BiP levels were highly elevated 
in all conditions (Figure 4). Increased expression of 
ATF4 was observed only in JLK1486 and TMZ + 2 µM 
JLK1486-treated cells (Figure 4). Induction began three 
days post treatment and was maintained 21 days post 
treatment, suggesting generation of long-term ER stress 
(Figure 4). We did find strong expression of ATF4 in 
day 14 DMSO-treated cells (Figure 4). We suggest this 
induction is due to nutritional deprivation resulting from 
these rapidly proliferating cells becoming overgrown. This 
is substantiated by a slight decrease in day 14 trypan blue 
negative cell number (Figure 3A) as well as the lack of 
increased and sustained CHOP induction of day 14, 19, 
and 21 DMSO versus 2 µM JLK1486 alone or TMZ + 
2 µM JLK1486-treated samples (Figure 4). Induction of 
CHOP was not observed until 9 days post 2 µM JLK1486 
and TMZ + 2 µM JLK1486 treatment (Figure 4). CHOP 
levels were maintained until day 14 in 2 µM JLK1486 
alone and TMZ + 2 µM JLK1486-treated cells. Increased 
CHOP expression was detected in TMZ + 2 µM JLK1486-
treated cells in day 19 and day 21 lysates (Figure 4). ATF4 
and CHOP were undetectable in all day 23 protein lysates 
(Figure 4). Induction of BiP and ATF4 in 2 µM JLK1486 
and TMZ + 2 µM JLK1486-treated cells suggests that 
JLK1486 is an effective ER stress-inducing agent and may 
promote cell death via prolonged ATF4 expression driving 
CHOP in TMZ + 2 µM JLK1486-treated cells.
tMZ+JlK1486 treatment triggers prolonged 
activation of dnA damage response pathway and 
promotes unresolved dnA double stand breaks
TMZ induces the formation of DNA DSBs. This 
results in phosphorylation of DNA damage sensors, 
ATM and CHK2, which in turn induces phosphorylation 
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Figure 3: tMZ+JlK1486 double treatment results in decreased cell growth and increased cell death in u87ns cells. 
(A) The number of trypan blue negative cells in U87NS cells treated with DMSO, 1 µM JLK1486, 2 µm JLK1486, 200 µM TMZ, TMZ 
+ 1 µM JLK1486, and TMZ + 2 µm JLK1486 collected over 24 hours to 23 days (n = 3). (b) Quantification of the number of trypan blue 
negative U87NS cells in DMSO, 1 µM JLK1486, 2 µm JLK1486, 200 µM TMZ, TMZ + 1 µM JLK1486, and TMZ + 2 µm JLK1486 
conditions at day 23 (n = 3). (c) The percent of trypan blue positive cells in U87NS cells treated with DMSO, 1 µM JLK1486, 2 µm 
JLK1486, 200 µM TMZ, TMZ +1 µM JLK1486, and TMZ + 2 µm JLK1486 collected over a 24 hour to 23 day time course (n = 3). 
(d) Quantification of the percent of trypan blue positive U87NS cells in DMSO, 1 µM JLK1486, 2 µm JLK1486, 200 µM TMZ, TMZ + 1 
µM JLK1486, and TMZ +2 µm JLK1486 conditions at day 23 (n = 3). (e–H) Representative FACs analysis comparing propidium versus 
annexin V staining of day 23 U87NS cells treated with DMSO, 2 µm JLK1486, 200 µM TMZ, and TMZ+2 µm JLK1486 (n = 4). (I) Percent 
of PI and Annexin V double negative cells in day 23 U87NS cells treated with DMSO, 2 µm JLK1486, 200 µM TMZ, and TMZ + 2 µm 
JLK1486 (n = 4). (J) Percent of PI and Annexin V double positive cells in day 23 U87NS cells treated with DMSO, 2 µm JLK1486, 200 µM 
TMZ, and TMZ + 2 µm JLK1486 (n = 4). All error bars are SEM, two-tailed t-test, *P = 0.01–0.02, **P = 0.001–0.008, ***P = 0.0007.
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of H2A.X, a key marker for DSBs, and recruitment of 
RAD51 to DSBs to initiate homologous recombination 
[46–48]. To determine if the combination of TMZ + 
2 µM JLK1486 increases and/or prolongs DNA damage, 
we analyzed a series of protein lysates collected from 
24 hours to 23 days post treatment for P ATM, ATM, 
P CHK2, CHK2, RAD51, and γH2A.X. 
We observed phosphorylation of ATM and CHK2 
24 hours post treatment in TMZ and TMZ + 2 µM 
JLK1486-treated cells (Figure 5). Increased levels of P 
ATM and P CHK2 were maintained in TMZ and TMZ + 
2 µM JLK1486-treated cells throughout the time-course, 
however, we noted higher levels of P ATM and P CHK2 in 
post day 14 combination lysates, suggesting TMZ + 2 µM 
JLK1486 treatment results in a sustained DNA damage 
response (Figure 5). Additionally, we detected extended 
phosphorylation of H2A.X in TMZ + 2 µM JLK1486-
treated cells, suggesting substantially more unresolved 
DNA DSBs in combination versus TMZ single treated cells 
(Figure 5; Supplementary Figure 2). Although high levels of 
RAD51 were initially observed in all conditions, we found 
RAD51 levels decreased 5 days post treatment in 2 µM 
JLK1486 alone and TMZ + 2 µM JLK1486-treated cells 
and were continually lower than TMZ alone treated cells 
until 21 days post treatment (Figure 5). Increased expression 
of RAD51 was not detected until 23 days post treatment. 
Detection of increased P ATM, P CHK2, and prolonged 
γH2A.X in TMZ + 2 µM JLK1486 cells suggests that 
combination treatment not only prolongs the DNA damage 
response, but also promotes unresolved DNA DSBs over an 
extended time course through reduction of RAD51.
Knockdown of AtF4 does not rescue secondary 
sphere formation but does decrease cell death in 
tMZ+JlK1486 treated cells
Because we observed inhibition of secondary sphere 
formation (Figure 2), increased cell death (Figure 3) and 
prolonged expression of ATF4 in TMZ + 2 µM JLK1486- 
treated cells (Figure 4), we asked if knockdown of ATF4 
would rescue secondary sphere formation and decrease 
cell death. To determine this, we generated three stable 
U87NS lines, one expressing an shRNA control, and 
two lines expressing shRNAs against ATF4, shATF4 C1 
and shATF4 E7. The U87NS sh control, shATF4 C1, 
and shATF4 E7 lines were treated with DMSO, 2 µM 
JLK1486, 200 µM TMZ, and TMZ + 2 µM JLK1486, 
protein lysates were collected at 24 hours and five days 
post treatment, and ATF4 levels were examined via 
western. Because neurosphere and trypan blue assays were 
carried out with cells plated at passage four and assays 
completed by passage six, we analyzed ATF4 expression 
levels in our knockdown lines at passage number six to 
verify that knockdown was maintained throughout the 
experimental time-course. We observed robust induction 
of ATF4 in 2 µM JLK1486 and TMZ + 2 µM JLK1486 sh 
control treated U87NS cells, slight induction of ATF4 in 
2 µM JLK1486 and TMZ + 2 µM JLK1486 shATF4 C1 
treated U87NS cells, and no expression of ATF4 in 2 µM 
JLK1486 and TMZ + 2 µM JLK1486 shATF4 E7 treated 
U87NS cells (Figure 6F). 
To determine if knockdown of ATF4 rescues 
secondary sphere formation, we treated our sh control, 
Figure 4: tMZ+JlK1486 treatment induces prolonged endoplasmic reticulum stress that results in induction of 
cHoP, a pro-apoptotic transcription factor. Western blot analysis of ER stress response factors, BiP, ATF4, and CHOP in whole 
cell U87NS lysates harvested after 24 hours to 23 days treatment of DMSO, 2 µM JLK1486, 200 µM TMZ, and TMZ + 2 µM JLK1486. 
Blots are representatives of n = 3.
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shATF4 C1, and shATF4 E7 U87NS lines with DMSO, 
2 µM JLK1486, 200 µM TMZ, and TMZ + 2 µM 
JLK1486 and carried out neurosphere assays. On day 21, 
we did not observe formation of secondary spheres in the 
U78NS sh control or in either of our U87NS shATF4 lines, 
C1 or E7, demonstrating that knockdown of ATF4 does 
not rescue secondary sphere formation in TMZ + 2 µM 
JLK1486-treated cells (Figure 6A–6C).
 As neurosphere assays may not evaluate the effect 
drug treatment has on viability, we determined if ATF4 
knockdown decreased cell death in our U87NS sh control 
and shATF4 C1 and E7 lines by carrying out a time course 
of trypan blue counts. As increased cell death in U87NS 
TMZ +2 µM JLK1486-treated cells was most significant 
at later time points (Figure 3), we focused on analyzing 
the number of trypan-blue-positive cells in our control 
and ATF4 knockdown lines at day 16, 19, and 21 time 
points. Furthermore, because U87NS cells treated with 
TMZ alone had significant reduction in cell growth, 
but were able to repopulate the culture versus TMZ + 2 
µM JLK1486-treated cells (Figure 3B), we were most 
interested in comparing the effects of ATF4 knockdown 
in TMZ versus TMZ + 2 µM JLK1486-treated cells (all 
conditions shown in Supplementary Figure 3). 
We observed a statistically significant decrease 
in the number of trypan-blue-positive cells in ATF4 
knockdown versus sh control TMZ + 2 µM JLK1486-
treated cells at day 19 and day 21 (Figure 6D–6E; Day 
19: C1 = 31%; E7 = 24%; control = 53%) (Figure 6D–6E; 
Day 21: C1 = 32%; E7 = 18%; control = 56%). Reduction 
of cell death in ATF4 U87NS knockdown cells treated 
with TMZ + 2 µM JLK1486 suggests ATF4 may play a 
role in promoting cell death in TMZ + 2 µM JLK1486-
treated cells. 
Figure 5: tMZ+JlK1486 treatment triggers prolonged activation of dnA damage response pathway and promotes 
unresolved dnA double stand breaks. Western blot analysis of DNA damage sensors (P ATM, ATM, P CHK2, CHK2) and markers 
for DNA DSBs (RAD51, ΥH2A.X) from whole cell U87NS lysates harvested after 24 hours to 23 days of DMSO, 2 µM JLK1486, 200 µM 
TMZ, and TMZ + 2 µM JLK1486 treatment. Blots are representatives of n = 3.
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To explore why ATF4 knockdown results in 
decreased cell death in TMZ + 2 µM JLK1486-treated 
cells, we analyzed levels of RAD51 in sh control versus 
shATF4 U87NS treated with DMSO, 2 µM JLK1486, 
200 µM TMZ, and TMZ + 2 µM JLK1486. We analyzed 
lysates collected 24 hours and 5 days post treatment as we 
saw decreased expression of RAD51 in 2 µM JLK1486 
and TMZ + 2 µM JLK1486 U87NS treated cells at day 5 
(Figure 5). Interestingly, we observed increased RAD51 
levels in shATF4 knockdown lines versus sh control 
U87NS cells after 5 days of TMZ + 2 µM JLK1486 
treatment (Figure 6F). This suggests a potential inverse 
relationship between ER stress induction of ATF4 and 
RAD51 protein levels.
TMZ+JLK1486 treatment delays tumor 
doubling in vivo 
To determine if the combination of TMZ+JLK1486 
is effective in vivo, we subcutaneously injected nude mice 
with U87NS cells, allowed tumors to form, and treated 
with DMSO, JLK1486 15 mg/kg, TMZ 5 mg/kg, or TMZ 
with JLK1486 (Figure 7A). We used time to tumor volume 
doubling as our readout to compare control, single agent, 
and double agent treated mice.
We found significant delay in tumor doubling 
in JLK1486 versus DMSO (p = 0.0002), TMZ versus 
DMSO (p = 0.0005), TMZ versus JLK1486 (p = 0.0007), 
TMZ+JLK1486 versus JLK1486 (p = 0.0003), and 
TMZ+JLK1486 versus TMZ alone (p = 0.04) treated 
mice (Figure 7B). This significant delay in tumor volume 
doubling for TMZ+JLK1486-treated mice suggests the 
combination should be further studied as it may have 
clinical applications.
dIscussIon 
There is an urgent need to improve the current 
chemotherapy for GBM patients. We determined if the 
addition of a novel ER stress inducer, JLK1486, would 
increase the efficaciousness of TMZ treatment. We 
reasoned that targeting two different pathways essential 
to tumor survival would inhibit GBM cell proliferation 
and promote cell death. We found that when GBM 
cells were treated with TMZ+JLK1486, we were able 
to reduce secondary sphere formation and in the case 
of U87NS cells, completely block secondary sphere 
formation, suggesting that this combination is effective 
at inhibiting tumor cells from re-populating their culture. 
This is an important finding as GBM therapies fail due 
to tumor recurrence [2, 3]. The mechanism of secondary 
sphere inhibition in U87NS cells is increased cell death. 
Interestingly, this effect was maintained over an extended 
time course, suggesting the combination provides a 
long-term effect. Furthermore, we found that treatment 
of subcutaneous tumors in mice with TMZ+JLK1486 
significantly delayed tumor doubling, suggesting the 
potential use of the combination in a clinical setting. We 
propose two models by which TMZ+JLK1486 promote 
cell death. One in which prolonged, unresolved ER stress 
drives apoptosis and one in which the accumulation of 
unrepaired, deleterious DNA double strand breaks triggers 
apoptosis.
To understand the mechanism driving the enhanced 
efficacy observed in TMZ+JLK1486 U87NS treated cells 
we delineated the effects the combination exerted on the 
ER stress response pathway, with particular attention to 
levels of ATF4 and CHOP induction. It is well established 
that GBM cells are reliant upon the ER stress pathway 
and that overwhelming the ER stress pathway switches the 
initial pro-survival response to one of pro-death. JLK1486 
is a viable candidate for this as it prevents the formation 
of disulfide bonds that are essential for protein folding and 
functionality. Indeed, when U87NS cells are treated with 
JLK1486 we see induction of ATF4 and its downstream 
target, CHOP, in JLK1486-treated cells, not TMZ- 
treated cells. This validates our hypothesis that JLK1486 
and TMZ target different pathways and reinforces the 
reasoning for why this dual treatment provides a robust 
response. 
We noted a decrease in ATF4 levels in day 7 
JLK1486 alone and TMZ+JLK1486 protein lysates. 
We found this intriguing as our initial drug regiment, 
(Supplementary Figure 1C) utilizing only one dose (1X) 
of JLK1486 at day 0 in combination with TMZ did not 
result in U87NS secondary sphere inhibition (Figure 2B). 
However, when we added a second dose (2X) of JLK1486 
at day 7, we observed complete inhibition of U87NS 
secondary sphere formation (Supplementary Figure 1D; 
Figure 2C). It is plausible the second dose of JLK1486 
at day 7 enhances inhibition of sphere formation by 
maintaining increased ATF4 levels that contribute to 
a sustained and unresolved ER stress response. The 
expression levels of ATF4 correlates with increased 
expression of its downstream target, CHOP, further 
strengthening this model. Increased levels of CHOP, 
a driver of apoptosis, are not observed until after the 
second dose of JLK1486 on day 7, again suggesting the 
second dose of JLK1486 is necessary to prolong ER stress 
levels and force the pro-survival to pro-apoptotic switch 
that contributes to reduced secondary spheres and cell 
death (Figure 2C; Figure 3; Figure 4). Sustained ATF4 
and CHOP expression in TMZ+JLK1486-treated cells 
correlates with our trypan blue positive time course, which 
shows increased cell death post day 14 (Figure 3C–3D). 
This suggests a model in which TMZ+JLK1486 treatment 
initiates, maintains, and promotes unresolved ER stress 
that drives apoptosis. 
TMZ treatment results in the formation of DNA 
DSBs. If these breaks are not repaired, cells undergo 
apoptosis. Both TMZ alone and TMZ+JLK1486-treated 
samples show induction of DNA damage at early and late 
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time-points; however, TMZ+JLK1486-treated samples 
exhibit stronger activation at later time points (Figure 5), 
suggesting prolonged DNA damage. Although both TMZ 
alone and TMZ+JLK1486 samples exhibit markers for 
unresolved DNA DSBs, only TMZ-treated cells have 
increased expression of RAD51, a key protein required for 
repair of DSBs. RAD51-mediated repair of DSBs would 
lead to cell survival and proliferation. We find this to be 
true in our TMZ alone treated cells where trypan blue 
positive counts decrease and trypan blue negative counts 
increase over time (Figure 3). Conversely, the decreased 
levels of RAD51 observed in TMZ+JLK1486-treated cells 
Figure 6: Knockdown of AtF4 does not rescue secondary sphere formation but does decrease cell death in 
tMZ+JlK1486 treated cells. (A) Secondary sphere formation of U87NS sh control cells treated with both TMZ+2 µM JLK1486 on 
day 0 and with 2 µM JLK1486 on day 7 (n = 3). (b) Secondary sphere formation of U87NS shATF4 C1 cells treated with both TMZ+2 
µM JLK1486 on day 0 and with 2 µM JLK1486 on day 7 (n = 3). (c) Secondary sphere formation of U87NS shATF4 E7 cells treated 
with both TMZ+2 µM JLK1486 on day 0 and with 2 µM JLK1486 on day 7 (n = 3). (d) Percent of trypan blue positive cells in U87NS 
sh control versus shATF4 C1 after 16, 19, and 21 days of 200 µM TMZ versus TMZ+2 µM JLK1486 treatment (n = 3). (e) Percent of 
trypan blue positive cells in U87NS sh control versus shATF4 E7 after 16, 19, and 21 days of 200 µM TMZ versus TMZ + 2 µM JLK1486 
treatment (n = 3). (F) Western blot analysis of RAD51 and ATF4 protein extracted from whole cell U87NS sh control, U87NS shATF4 C1, 
and U87NS shATF4 E7 cells treated with DMSO, 2 µM JLK1486, 200 µM TMZ, TMZ + 2 µM JLK1486 for either 24 hours or 5 days. 
NC = not counted because neurospheres too numerous. Representative blot shown (n = 3). All error bars are SEM, two-tailed t-test, 
*P = 0.03,**P = 0.008, ***P = 0.001-0.003,****P = 0.0001–0.0007.
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would lead to accumulation of un-resolved DNA DSBs, 
prolonged γH2A.X induction and increased cell death. 
This pattern is exhibited in TMZ+JLK1486-treated samples 
where RAD51 levels are substantially lower than TMZ 
alone treated samples, correlating with increased DNA 
DSBs (Figure 5; Supplementary Figure 3). Accumulation 
of un-resolved DNA DSBs due to decreased RAD51 levels 
is a plausible second mechanism for why TMZ+JLK1486-
treated cells are unable to re-populate and instead initiate 
apoptosis (Figure 3H; Figure 5; Figure 8). 
Figure 7: tMZ+JlK1486 treatment delays tumor doubling in vivo. (A) Dosing schedule implemented for NU/NU mice 
intraperitoneal (IP) injected with DMSO vehicle, JLK1486 15mg/kg, TMZ 5 mg/kg or both drugs. (b) Kaplein-Meier survival curve 
comparing time to tumor doubling in DMSO, JLK1486 15mg/kg, TMZ 5 mg/kg, and combination treated NU/NU mice. JLK1486 vs. 
DMSO ***P = 0.0002; TMZ vs. DMSO P = 0.0005; TMZ+JLK1486 vs. DMSO P = 0.0002; TMZ vs. JLK1486 P = 0.0007; TMZ+JLK1486 
vs. JLK1486 ***P = 0.0003; TMZ+JLK1486 vs. TMZ *P = 0.04. Statistics generated via a log-rank test.
Figure 8: tMZ+JlK1486 treatment induces prolonged er stress and unresolved dnA damage that results in increased 
cell death. TMZ activates the DNA damage response pathway due to the generation of DNA double strand breaks. If the breaks are 
repaired, the cells survive; if not, cells undergo apoptosis. JLK1486 induces ER stress. If ER stress is resolved, cells survive; if not, cells 
undergo apoptosis through ATF4 mediated up-regulation of CHOP. TMZ+2 µM JLK1486 treatment prolongs ER stress, activates the DNA 
damage response, and causes unresolved DNA DSBs that result in apoptosis due to decreased RDA51 levels, possibly mediated by ER 
stress induced ATF4 expression. GBM cells generate resistance to TMZ through several mechanisms, including increased expression of 
methyl guanine methyl transferase (MGMT), which removes alkyl groups from O6 guanine residues, and mutations of the mismatch repair 
(MMR) system, allowing aberrant cells to enter and complete the cell cycle.
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As we suggest two possible mechanisms that 
account for induction of cell death in TMZ+JLK1486-
treated cells, one due to prolonged ER stress and the 
second due to unresolved DNA DSBs, we asked if a 
link between ER stress induction and RAD51 protein 
reduction could be found. When ATF4 is strongly 
expressed in JLK1486 and TMZ+JLK1486-treated 
samples, we observed reduction of RAD51 protein 
levels (Figure 4; Figure 5; Figure 6F). Conversely, 
when ATF4 levels decrease over time, as in day 23 
samples (Figure 4) or are reduced via shRNA (Figure 6), 
RAD51 increases (Figure 5; Figure 6F) This suggests 
a potential novel inverse relationship where ER stress, 
possibly through ATF4 induction, decreases RAD51 
levels (Figure 8). Although the potential mechanism of 
how ATF4 may regulate RAD51 expression is beyond 
the scope of this study, one could envision several 
possibilities. Perhaps ATF4 itself acts as a repressor 
of RAD51 transcription or drives the expression of 
RAD51 repressors or miRs that negatively regulate 
RAD51 translation. Nonetheless, it may serve as a novel 
interaction to be explored. Supporting this, Yamamori et 
al reported that ER stress in lung carcinoma cells leads 
to enhanced proteasomal degradation of Rad51 [43]. 
In conclusion, we suggest that TMZ+JLK1486 is an 
effective novel drug combination that results in cell death 
of U87NS cells due to the combination of prolonged 
ER stress induction and the inability to resolve DNA 
damage through RAD51 reduction. As this study was 
being prepared for publication, Xipell et al proposed a 
similar model by which ER stress suppresses multiple 
DNA repair proteins [49].
MAterIAls And MetHods
cell lines and cell culture reagents
U87MG, A172, T98G, and LN18 cell lines were 
purchased from American Type Culture Collection 
(ATCC). U118MG cells were a kind gift from the 
laboratory of Dr. Larry Recht (Stanford University, 
Stanford, CA, 2003). Cell lines were verified via the 
Radil Idexx Cell Check (9 short tandem repeats) and 
maintained as monolayers in 10% FBS / DMEM (GIBCO; 
#11965-092) at 5% C02. 5075 and GS8-26 primary GBM 
lines were acquired from the UMASS tissue bank and 
maintained in defined medium DMEM/F12 1:1, 15 mM/L 
HEPES, 1X B27 without vitamin A, and supplemented 
with 20 ng/mL bFGF and EGF [45]. The establishment 
of the primary line GS8-26 has been presented [45]. The 
5075 primary line was prepared in a similar procedure 
except Liberase instead of trypsin was used to digest the 
tumor [50]. U87NS and U118NS neurosphere lines were 
generated from adherent lines, maintained, and passaged 
as previous described [45]. 
reagents
Temozolomide (T2577) was purchased from Sigma-
Aldrich, re-suspended at 10 mg/mL in 100% DMSO, 
aliquoted, and stored at –20°C. The synthesis and structure 
of JLK1486 synthesis was previously described [20, 51]. 
JLK1486 was re-suspended at 10 mM in 100% DMSO, 
aliquoted, and stored at –20°C. 
Mts assay
The IC50s’ of adherent lines was determined by 
plating 1 × 103 cells/100 uL in 96 well plates and after 
24 hours treating the adherent cells with increasing 
concentrations of JLK1486 (0 µM – 100 µM). Media 
was aspirated five days later and replaced with CellTiter 
96 Aqueous One Solution Cell Proliferation Assay (MTS; 
Promega G35A) for ~3 hours. Plates were read at A490 nm.
Primary and secondary neurosphere assays
Neurosphere assays were carried out as previously 
described [52]. Briefly, U87NS, U118NS, GS8-26, and 
5075 lines were pH dissociated, filtered (40 µm), plated at 
6,000 cells /2 mL in 6 well plates, and treated with DMSO, 
JLK1486, TMZ, or TMZ+JLK1486. Primary spheres were 
counted, fed, and dosed with JLK1486 a second time on 
day 7 for U87 and U118 and on day 10 for primary lines 
GS8-26 and 5075. Sphere recovery was determined by 
counting spheres 7 or 10 days later, day 14 for U87NS 
and U118NS and day 20 for primary lines. Spheres were 
then pH dissociated, diluted (U87NS, U118NS: DMSO 
= 1:100; JLK1486 = 1:50; TMZ = 1:1; TMZ+JLK1486 
= 1:1; 5075, GS8-26: DMSO = 1:25; JLK1486 = 1:2; 
TMZ = 1:2; TMZ+JLK1486 = 1:1), re-plated, and counted 
7 or 10 days later, day 21 for U87NS and U118NS and day 
30 for 5075 and GS8-26 lines , to determine secondary 
sphere formation capability.
Western blotting
Cells were lysed in RIPA Buffer (Boston BioProducts 
#BP-115), supplemented with protease inhibitor cocktail 
tablets (Roche, complete mini, #11 836 153 001), and 5 
mM NaF. Protein was quantified via Bio-RAD Protein 
Assay Dye Reagent Concentrate (BIO-RAD, #500-0006) 
on the Beckman Coulter DU640 Spectrophotometer. 
Proteins were separated by PAGE and electo-transferred 
to PVDF membranes (Pall Corporation, BioTrace PVDF 
0.45 um, P/N 66543). Membranes were blocked in 5% 
milk tris-buffered saline with tween 20 (0.1%; TBS-T). 
Primary antibodies were incubated overnight on a rocker 
in 5% bovine serum albumin in TBS-T at 1:1000 at 4°C. 
Membranes were washed the following day 3×, 5′, TBS-T, 
and incubated with either mouse or rabbit horseradish 
peroxidase secondary (Cell Signaling #7076S and #7074) 
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for 2 hours room temperature. Proteins were detected via 
film following the Thermo Scientific’s SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Fisher Scientific, 
#34087) or Thermo Scientific’s SuperSignal West Femto 
Maximum Sensitivity Substrate (#34095) protocol. The 
following antibodies were purchased from Cell Signaling 
Technology: B-Actin (#3700), BiP (#3177), CHOP (#2895), 
ATF-4 (#11815), Rad51 (#8875), Phospho-Histone H2A.X 
(#2577), H2A.X (#2595), ATM (#2873), Phospho-ATM 
(#13050), CHK2 (#6334), Phospho-Chk2 (#2661). 
trypan blue positive and negative counts
U87NS cells were pH dissociated, filtered, and 
plated at 250,000/10mL in T75 flasks. Cells were treated 
with DMSO, JLK1486, TMZ, or TMZ+JLK1486. On day 
7 cells were given fresh media and dosed a second time 
with JLK1486. On day 14 cells were pH dissociated and 
re-plated at 172,000/10mL in T75 flasks. Cells were pH 
dissociated and positive and negative trypan blue cells 
(GIBCO, Trypan Blue Stain 0.4%, #15250) were counted. 
FAcs analysis
Drug treated U87NS were pH dissociated, filtered, 
washed 3X in PBS, and fixed in 95% ethanol overnight 
at 4°C. Propidium iodide versus Annexin V staining was 
performed by the UMASS FACS Core, and samples 
were run on the Calibur FACS machine. Analysis was 
completed using Flow Jo 7.6 
shrnA AtF4
pGIPZ shATF4 C1 (OligoID: V2LHS_132755), 
shATF4 E7 (OilgoID: VDLHS_132757), and sh Control 
were purchased from the UMASS RNAi Core Facility. 
U87MG cells were infected according to the UMASS RNAi 
Core Facility Protocol. Briefly, 1 × 105 cells/well were plated, 
infected 24 hours later with viral supernatant and 1 µg/µl 
polybrene (Millipore, TR-1003-G), media changed 24 hours 
post infection and cells were selected for seven days in 2 
µg/mL puromycin (GIBCO, #A11138-03). Infected U87MG 
cells were then converted to U87NS cells as described above.
ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the author’s 
institutional review board.
Mouse xenograft models
Six-week old male NU/NU mice were purchased 
from Charles River Laboratories and injected with 
1 × 106 U87NS cells in 100 uL PBS/ right flank. When 
tumor volumes reached 150 mm3 mice were dosed 
intraperitoneal (IP) with either DMSO (day 0, day3, day 6, 
day 9), JLK1486 15 mg/kg (day 0, day 7), TMZ 5 mg/ kg 
(day 0, day 7) or with the following dosing regimen: 
TMZ 5 mg/ kg (day 0), JLK 1486 15 mg/kg (day 3), TMZ 
5 mg/kg (day 6), JLK1486 15 mg/kg (day 9). Mice were 
sacrificed when tumors reached 1200 mm3.
H2A.X Immunofluoresence staining
U87NS cells were adhered to slides using Double 
Cytofunnel Disposable Chambers (Thermo Scientific, 
#5991039), fixed in 4%PFA/PBS (10 minutes), 
permeabilized in .5% TRITON X/ PBS (5 minutes), blocked 
in normal goat serum (1 hour), stained overnight with 
either Phospho-Histone H2A.X (Ser139) (Cell Signaling, 
#2577) or Rabbit (DA1E) mAb IgG XP Isotype Control 
(Cell Signaling, #3900), washed in 1X PBS, incubated with 
goat anti-rabbit IgG (H+L) Secondary Antibody, Alexa 
Fluor 568 (Life Technologies, #A-11011), and mounted via 
ProLong Gold Antifade Mountant with DAPI (Molecular 
Probes by Life Technologies, #P36941). Images were 
acquired with a Leica wide field scope microscope.
statistical analysis in vitro
The t-test analysis was performed using GraphPad 
Prism version 6.00 for Mac, GraphPad Software, La Jolla 
California, USA, www.graphpad.com
statistical analysis in vivo
Kaplan-Meier time to tumor volume doubling 
curves were analyzed via log-rank test.
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